ClinicalTrials.gg
CompletedNCT01181011Updated Jul 24, 2014Results posted

Telmisartan, Amlodipine and Combination in Healthy Subjects

A Phase 1 interventional study of amlodipine/telmisartan/combination in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-07-24.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

To determine the pharmacokinetic profile of 80 mg telmisartan / 5 mg amlodipine (T80/A5) dose combination after single dose in healthy Chinese subjects.

To determine whether a pharmacokinetic interaction exists between telmisartan and amlodipine, following single doses of 80mg telmisartan (T80), and 5 mg amlodipine (A5) tablet alone and in combination, in healthy Chinese subjects.

To evaluate the safety and tolerability of T80 and A5 alone and in combination in healthy Chinese subjects.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy males and females
  2. Aged between 18 and 45 years
  3. Body weight more than 50Kg , and (BMI ) between 19 and 24 kg/m2

Exclusion criteria

Exclusion criteria

  1. Any finding of the medical examination deviating from normal and of clinical relevance
  2. Any evidence of a concomitant disease
  3. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  4. Surgery of the gastrointestinal tract (except appendectomy)
  5. Diseases of the central nervous system or psychiatric disorders or neurological disorders
  6. History of relevant orthostatic hypotension, fainting spells or blackouts.
  7. Chronic or relevant acute infections
  8. History of relevant allergy/ (including allergy to drug or its )
  9. Intake of drugs with a long half-life (> 24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial
  10. Use of drugs which might reasonably influence the results of the trial
  11. Participation in another trial with an drug within two months prior to administration or during the trial
  12. Smoker
  13. Inability to refrain from smoking during 24 hours prior to dosing and during the trial
  14. Alcohol abuse or inability to stop alcoholic beverages for 24 hours prior to dosing and during the trial
  15. Drug abuse
  16. Blood donation (more than 100 mL within four weeks prior to administration or during the trial)
  17. Excessive physical activities (within one week prior to administration or during the trial)
  18. Any laboratory value outside the reference range that is of clinical relevance
  19. Inability to comply with dietary regimen of trial site
  20. A history of additional risk factors for torsade de pointes
  21. Any history of relevant low blood pressure
  22. Supine blood pressure at screening of systolic \<110 mm Hg and diastolic \< 60 mm Hg
  23. History of urticaria
  24. History of angioneurotic edema 25 Pregnancy / positive pregnancy test, or planning to become pregnant during the study or within 1 month of study completion
  1. No adequate during the study and until 1 month of study completion 27. Lactation period
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    amlodipine/telmisartan/combination

    all patients will be assigned to 6 treatment sequences. cross-over design was adopted to ensure each patient would take amlodipine/telmisartan/combination single dose in randomized order

    Drug: amlodipine/telmisartan/combination

Interventions

  • Drugamlodipine/telmisartan/combination

    patient would take amlodipine(5mg)/telmisartan(80mg)/combination(T80+A5mg) single dose in random order, and each dosage will be separated in 21 days interval.

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-time Curve of Telmisartan in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point (AUC_0-tz)

    Time frame: 3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs

  2. Area Under the Plasma Concentration-time Curve From the Time of Dosing to Infinity (AUC_0-∞) of Telmisartan

    Time frame: 3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs

  3. The Maximum Observed Plasma Concentration (Cmax) of Telmisartan

    Time frame: 3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs

  4. AUC_0-tz of Amlodipine

    Time frame: 3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs

  5. AUC_0-∞ of Amlodipine

    Time frame: 3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs

  6. Cmax of Amlodipine

    Time frame: 3 periods of single-dose treatment (8 days of sampling) separated by 21 days of wash-outs

Secondary outcomes

  1. Time to Attain Cmax (Tmax) of Telmisartan

    Time frame: 3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs

  2. Terminal Rate Constant in Plasma (λz) of Telmisartan

    reflect the speed of drug elimination in vivo

    Time frame: 3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs

  3. Mean Residence Time of Telmisartan in the Body After Oral Administration (MRT_po)

    Time frame: 3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs

  4. Elimination Half-life (t_½) of Telmisartan

    Time frame: 3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs

  5. Apparent Clearance of Telmisartan in Plasma Following Extravascular Administration (CL/F)

    Time frame: 3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs

  6. Apparent Volume of Distribution During the Terminal Phase λz Following an Extravascular Administration (V_z/F) of Telmisartan

    Time frame: 3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs

  7. Tmax of Amlodipine

    Time frame: 3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs

  8. λz of Amlodipine

    Time frame: 3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs

  9. MRT_po of Amlodipine

    Time frame: 3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs

  10. t_½ of Amlodipine

    Time frame: 3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs

  11. CL/F of Amlodipine

    Time frame: 3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs

  12. V_z/F of Amlodipine

    Time frame: 3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs

  13. Number of Participants With at Least One Treatment Emergent Adverse Event

    Time frame: 4 weeks

  14. Number of Participants With Clinically Relevant Findings in Electrocardiogram (ECG), Vital Signs, Physical Finding or Laboratory Finding Abnormalities

    Time frame: 4 weeks

07

Results

Posted May 10, 2012

Participant flow

Participant flow — Overall Study
MilestoneAll Participants
Started28
Received telmisartan 80mg27
Received telmisartan 80mg,amlodipine 5mg27
Received amlodipine 5mg26
Completed25
Not completed3
Withdrew: Adverse event2
Withdrew: Lost to follow-up1

Outcome measures

PrimaryArea Under the Concentration-time Curve of Telmisartan in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point (AUC_0-tz)
Time frame:
3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs
Reported as:
Geometric mean · ng·h/mL
Area Under the Concentration-time Curve of Telmisartan in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point (AUC_0-tz)
ng·h/mLTelmisartan 80mg, Amlodipine 5mgTelmisartan 80mg
Area Under the Concentration-time Curve of Telmisartan in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point (AUC_0-tz)3200 ± 74.72940 ± 94.4
Statistical analysis
  • Telmisartan 80mg, Amlodipine 5mg vs Telmisartan 80mg · ANCOVA · p = 0.0107 (The p-value is for the ratio being outside the interval 0.8 to 1.25.) · Gmean ratio: 109.22 · 90% CI 99.45 to 119.95
PrimaryArea Under the Plasma Concentration-time Curve From the Time of Dosing to Infinity (AUC_0-∞) of Telmisartan
Time frame:
3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs
Reported as:
Geometric mean · ng·h/mL
Area Under the Plasma Concentration-time Curve From the Time of Dosing to Infinity (AUC_0-∞) of Telmisartan
ng·h/mLTelmisartan 80mg, Amlodipine 5mgTelmisartan 80mg
Area Under the Plasma Concentration-time Curve From the Time of Dosing to Infinity (AUC_0-∞) of Telmisartan3420 ± 82.53140 ± 98.5
Statistical analysis
  • Telmisartan 80mg, Amlodipine 5mg vs Telmisartan 80mg · ANCOVA · p = 0.0139 (The p-value is for the ratio being outside the interval 0.8 to 1.25.) · Gmean ratio: 109.84 · 90% CI 99.96 to 120.71
PrimaryThe Maximum Observed Plasma Concentration (Cmax) of Telmisartan
Time frame:
3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs
Reported as:
Geometric mean · ng/mL
The Maximum Observed Plasma Concentration (Cmax) of Telmisartan
ng/mLTelmisartan 80mg, Amlodipine 5mgTelmisartan 80mg
The Maximum Observed Plasma Concentration (Cmax) of Telmisartan461 ± 59.9480 ± 78.3
Statistical analysis
  • Telmisartan 80mg, Amlodipine 5mg vs Telmisartan 80mg · ANCOVA · p = 0.0126 (The p-value is for the ratio being outside the interval 0.8 to 1.25.) · Gmean ratio: 97.57 · 90% CI 84.643 to 112.472
PrimaryAUC_0-tz of Amlodipine
Time frame:
3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs
Reported as:
Geometric mean · ng·h/mL
AUC_0-tz of Amlodipine
ng·h/mLTelmisartan 80mg, Amlodipine 5mgAmlodipine 5mg
AUC_0-tz of Amlodipine206 ± 28.6192 ± 31
Statistical analysis
  • Telmisartan 80mg, Amlodipine 5mg vs Amlodipine 5mg · ANCOVA · p = 0.0011 (The p-value is for the ratio being outside the interval 0.8 to 1.25.) · Gmean ratio: 109.7 · 90% CI 102.87 to 117.07
PrimaryAUC_0-∞ of Amlodipine
Time frame:
3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs
Reported as:
Geometric mean · ng·h/mL
AUC_0-∞ of Amlodipine
ng·h/mLTelmisartan 80mg, Amlodipine 5mgAmlodipine 5mg
AUC_0-∞ of Amlodipine225 ± 27.1210 ± 30.9
Statistical analysis
  • Telmisartan 80mg, Amlodipine 5mg vs Amlodipine 5mg · ANCOVA · p = 0.0006 (The p-value is for the ratio being outside the interval 0.8 to 1.25.) · Gmean ratio: 108.8 · 95% CI 102.1 to 116.0
PrimaryCmax of Amlodipine
Time frame:
3 periods of single-dose treatment (8 days of sampling) separated by 21 days of wash-outs
Reported as:
Geometric mean · ng/mL
Cmax of Amlodipine
ng/mLTelmisartan 80mg, Amlodipine 5mgAmlodipine 5mg
Cmax of Amlodipine4.72 ± 21.74.43 ± 27.3
Statistical analysis
  • Telmisartan 80mg, Amlodipine 5mg vs Amlodipine 5mg · ANCOVA · p = 0.000 (The p-value is for the ratio being outside the interval 0.8 to 1.25.) · Gmean ratio: 106.7 · 90% CI 100.9 to 112.9
SecondaryTime to Attain Cmax (Tmax) of Telmisartan
Time frame:
3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs
Reported as:
Mean · h
Time to Attain Cmax (Tmax) of Telmisartan
hTelmisartan 80mg, Amlodipine 5mgTelmisartan 80mg
Time to Attain Cmax (Tmax) of Telmisartan1.22 ± 0.581.16 ± 0.76
SecondaryTerminal Rate Constant in Plasma (λz) of Telmisartan

reflect the speed of drug elimination in vivo

Time frame:
3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs
Reported as:
Mean · 1/h
Terminal Rate Constant in Plasma (λz) of Telmisartan
1/hTelmisartan 80mg, Amlodipine 5mgTelmisartan 80mg
Terminal Rate Constant in Plasma (λz) of Telmisartan0.0305 ± 0.01140.0323 ± 0.0124
SecondaryMean Residence Time of Telmisartan in the Body After Oral Administration (MRT_po)
Time frame:
3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs
Reported as:
Mean · h
Mean Residence Time of Telmisartan in the Body After Oral Administration (MRT_po)
hTelmisartan 80mg, Amlodipine 5mgTelmisartan 80mg
Mean Residence Time of Telmisartan in the Body After Oral Administration (MRT_po)20.0 ± 4.818.4 ± 5.7
SecondaryElimination Half-life (t_½) of Telmisartan
Time frame:
3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs
Reported as:
Mean · h
Elimination Half-life (t_½) of Telmisartan
hTelmisartan 80mg, Amlodipine 5mgTelmisartan 80mg
Elimination Half-life (t_½) of Telmisartan27.0 ± 13.725.0 ± 10.7
SecondaryApparent Clearance of Telmisartan in Plasma Following Extravascular Administration (CL/F)
Time frame:
3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs
Reported as:
Mean · L/h
Apparent Clearance of Telmisartan in Plasma Following Extravascular Administration (CL/F)
L/hTelmisartan 80mg, Amlodipine 5mgTelmisartan 80mg
Apparent Clearance of Telmisartan in Plasma Following Extravascular Administration (CL/F)31.0 ± 21.637.3 ± 39.7
SecondaryApparent Volume of Distribution During the Terminal Phase λz Following an Extravascular Administration (V_z/F) of Telmisartan
Time frame:
3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs
Reported as:
Mean · L
Apparent Volume of Distribution During the Terminal Phase λz Following an Extravascular Administration (V_z/F) of Telmisartan
LTelmisartan 80mg, Amlodipine 5mgTelmisartan 80mg
Apparent Volume of Distribution During the Terminal Phase λz Following an Extravascular Administration (V_z/F) of Telmisartan1021 ± 6971135 ± 1018
SecondaryTmax of Amlodipine
Time frame:
3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs
Reported as:
Mean · h
Tmax of Amlodipine
hTelmisartan 80mg, Amlodipine 5mgAmlodipine 5mg
Tmax of Amlodipine6.88 ± 1.747.20 ± 1.63
Secondaryλz of Amlodipine
Time frame:
3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs
Reported as:
Mean · 1/h
λz of Amlodipine
1/hTelmisartan 80mg, Amlodipine 5mgAmlodipine 5mg
λz of Amlodipine0.0305 ± 0.01140.0323 ± 0.0124
SecondaryMRT_po of Amlodipine
Time frame:
3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs
Reported as:
Mean · h
MRT_po of Amlodipine
hTelmisartan 80mg, Amlodipine 5mgAmlodipine 5mg
MRT_po of Amlodipine44.3 ± 7.043.7 ± 7.6
Secondaryt_½ of Amlodipine
Time frame:
3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs
Reported as:
Mean · h
t_½ of Amlodipine
hTelmisartan 80mg, Amlodipine 5mgAmlodipine 5mg
t_½ of Amlodipine38.8 ± 7.638.6 ± 7.5
SecondaryCL/F of Amlodipine
Time frame:
3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs
Reported as:
Mean · L/h
CL/F of Amlodipine
L/hTelmisartan 80mg, Amlodipine 5mgAmlodipine 5mg
CL/F of Amlodipine22.7 ± 6.325.1 ± 7.9
SecondaryV_z/F of Amlodipine
Time frame:
3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs
Reported as:
Mean · L
V_z/F of Amlodipine
LTelmisartan 80mg, Amlodipine 5mgAmlodipine 5mg
V_z/F of Amlodipine1241 ± 3131353 ± 369
SecondaryNumber of Participants With at Least One Treatment Emergent Adverse Event
Time frame:
4 weeks
Reported as:
Number · Participants
Number of Participants With at Least One Treatment Emergent Adverse Event
ParticipantsTelmisartan 80mg, Amlodipine 5mgTelmisartan 80mgAmlodipine 5mg
Number of Participants With at Least One Treatment Emergent Adverse Event424
SecondaryNumber of Participants With Clinically Relevant Findings in Electrocardiogram (ECG), Vital Signs, Physical Finding or Laboratory Finding Abnormalities
Time frame:
4 weeks
Reported as:
Number · Participants
Number of Participants With Clinically Relevant Findings in Electrocardiogram (ECG), Vital Signs, Physical Finding or Laboratory Finding Abnormalities
ParticipantsTelmisartan 80mg, Amlodipine 5mgTelmisartan 80mgAmlodipine 5mg
ECG abnormalities000
Vital signs abnormalities000
Physical finding abnormalities000
Laboratory finding abnormalities110

Adverse events

Collected over 4 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Telmisartan 80mg, Amlodipine 5mg—0/27 (0%)2/27 (7.4%)
Telmisartan 80mg—0/27 (0%)1/27 (3.7%)
Amlodipine 5mg—0/26 (0%)3/26 (11.5%)
Most frequent other events
Most frequent other events
EventTelmisartan 80mg, Amlodipine 5mgTelmisartan 80mgAmlodipine 5mg
InfluenzaInfections and infestations2/271/273/26

Baseline characteristics

Age, Continuous
Age, Continuous(Years)All Participants
Mean24 ± 2.0
Sex: Female, Male
Sex: Female, Male(Participants)All Participants
Female10
Male18
08

Study locations

1 site
  • 1235.30.86001 Boehringer Ingelheim Investigational Site
    Shanghai, China
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2010 and a primary completion of Nov 2010. It does not say whether these dates are actual or estimated.

Results were first posted in May 2012, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2010
First posted
Aug 13, 2010
Start
Aug 2010
Primary completionActual
Nov 2010
Results first posted
May 10, 2012
Last update
Jul 24, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01181011
Responsible party
Sponsor
First posted
Aug 13, 2010
Start date
Aug 2010
Primary completion
Nov 2010
Results posted
May 10, 2012
Last update
Jul 24, 2014

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion